|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interferon-a plus lamivudine vslamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B显示文摘AIM: To investigate the efficacy of combination treatment of IFN-α and lamivudine compared to lamivudine monotherapy, after 24 mo of administration in HBeAg-negative hepatitis B patients.METHODS: Fifty consecutive patients were randomly assigned to receive IFN-α-2b (5 MU thrice per week, n = 24) plus lamivudine (100 mg daily) or lamivudine only (n = 26) for 24 mo. Patients were followed up for further 6 mo. The primary outcome was the proportion with sustained virological response (undetectable serum HBV DNA concentrations) and or sustained biochemical response (transaminase levels within normal range) at 30 mo (6 mo after the end of therapy). Secondary end-points were timed from initial virological (biochemical) response to VBR (BBR, respectively) and the emergence of YMDD mutants across the two arms.RESULTS: Five of twenty-four (21%) patients in the combination arm vs 3/26 (12%) in the lamivudine arm had sustained response (i.e., normal serum transaminase levels and undetectable HBV DNA by PCR assay) 6 mo after treatment discontinuation. A reduction in the emergence of YMDD mutants and in the development of virological breakthroughs was observed in patients receiving combination treatment (10% vs46%, P= 0.01 and 14% vs46%, P= 0.03,respectively).Time from initial virologic response to virologic breakthrough (VBR) was greater among initial responders receiving combination treatment compared to those receiving lamivudine (22.9 mo vs 15.9 mo, respectively; P = 0.005).CONCLUSION: Our results demonstrate that IFN-α plus lamivudine combination therapy does not increase the sustained response, compared to lamivudine. However,combination therapy reduces the likelihood of VBR due to YMDD mutants and prolongs the time period until the breakthrough development. | Michalis Economou Spilios Manolakopoulos Thomas A Trikalinos Spyros Filis Sotiris Bethanis Dimitrios Tzourmakliotis Alec Avgerinos Sotiris Raptis Epameinondas V Tsianos | 2005 | World Journal of Gastroenterology2005，11，37： | 6 |
| 2 | Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis显示文摘CREB 有约束力的蛋白质(CBP ) 和它的相当或相同事物 p300 是涉及细胞的活动的一个宽数组的各种各样的顺序特定的抄写因素的 transcriptionalco 使活跃之物,例如脱氧核糖核酸修理,房间生长,区别和 apoptosis。Severalstudies 建议了 CBP 和 p300 可能被看作瘤压制 ors,与他们是的突出的角色响应各种各样的刺激的不同基因表示模式的跨 coupling。他们主要经由乙酰化施加行动嘘和另外的规章的蛋白质(例如 p53 ) 。在 CBP/p300 功能的主要悖论是他们似乎能够贡献各种各样的反对细胞的进程。呼吸上皮 tumorigenesis 代表一个范围的多步累积的一个复杂过程基因并且 epigenetic 错误。通过激活和压抑的建筑群的交替的形成的 Transcriptionmodulation 是这些精神错乱的最终的收敛点,并且 CBP/p300 在这相互影响代表关键参加者。因此,他们的分子的行动和相互作用的照明能在呼吸上皮 carcinogenesis 为药理学干预揭示新潜在的目标。 | Michalis V Karamouzis Panagiotis A Konstantinopoulos Athanasios G Papavassiliou | 2007 | Cell Research2007，17，4： | 5 |
| 3 | Steatosis and steatohepatitis in postmortem material from Northwestern Greece显示文摘AIM: To determine the prevalence of steatosis and steatohepatitis in a series of autopsies in Northwestern Greece. METHODS: Liver biopsy material from a total of 600 autopsies performed over a period of 2 years (2006-2008) to def ine the cause of death was subjected to histological examination. Patient demographic data were also collected. Tissue sections were stained with different dyes for the evaluation of liver architecture, degree of fibrosis and other pathological conditions when necessary. RESULTS: Satisfactory tissue samples for histological evaluation were available in 498 cases (341 male, 157 female) with a mean age of 64.51 ± 17.78 years. In total, 144 (28.9%) had normal liver histology, 156 (31.3%) had evidence of steatosis, and 198 (39.8%) had typical histological findings of steatohepatitis. The most common causes of death were ischemic heart disease with or without myocardial infarction (43.4%), and traffic accidents (13.4%). CONCLUSION: A high prevalence of steatosis and steatohepatitis was detected in postmortem biopsies from Northwestern Greece. Since both diseases can have serious clinical consequences, they should be considered as an important threat to the health of the general population in Greece. | Christos D Zois Gerasimos H Baltayiannis Anna Bekiari Anna Goussia Peter Karayiannis Michalis Doukas Demetrios Demopoulos Antigoni Mitsellou Theodoros Vougiouklakis Vasiliki Mitsi Epameinondas V Tsianos | 2010 | World Journal of Gastroenterology2010，16，31： | 4 |
| 4 | Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy显示文摘Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal diseases,with an average 5-year survival rate of less than 10%.Unfortunately,the majority of patients have unresectable,locally advanced,or metastatic disease at the time of diagnosis.Moreover,traditional treatments such as chemotherapy,surgery,and radiation have not been shown to significantly improve survival.Recently,there has been a swift increase in cancer treatments that incorporate immunotherapybased strategies to target all the stepwise events required for tumor initiation and progression.The results in melanoma,non-small-cell lung cancer and renal cell carcinoma are very encouraging.Unfortunately,the application of checkpoint inhibitors,including anti-CTLA4,anti-PD-1,and anti-PD-L1 antibodies,in pancreatic cancer has been disappointing.Many studies have revealed that the PDAC microenvironment supports tumor growth,promotes metastasis and consists of a physical barrier to drug delivery.Combination therapies hold great promise for enhancing immune responses to achieve a better therapeutic effect.In this review,we provide an outline of why pancreatic cancer is so lethal and of the treatment hurdles that exist.Particular emphasis is given to the role of the tumor microenvironment,and some of the latest and most promising studies on immunotherapy in PDAC are also presented. | Panagiotis Sarantis Evangelos Koustas Adriana Papadimitropoulou Athanasios G Papavassiliou Michalis V Karamouzis | 2020 | World Journal of Gastrointestinal Oncology2020，12，2： | 4 |
| 5 | Upgraded role of autophagy in colorectal carcinomas显示文摘Autophagy is a basic catabolic process closely asso-ciated with degradation of cellular components. The role of autophagy in colorectal cancer(CRC) remains controversial. The mechanism of autophagy has been identified as protecting mechanism against tumorige-nesis by isolation of damaged organelles or as cytopro-tective provides energy in hypoxic regions of CRC tumors. Mutations in proto-oncogenes, such as RAS and BRAF, have been associated with autophagy initiation through signaling pathways of BRAF/MEK/ERK and PI3 K/AKT/m TOR. A combination therapy of chemotherapeutic agents and autophagy inhibitors such as hydroxychloroquine or immunotherapy might represent a major step that could be evaluated as a putative novel therapeutic strategy in CRC patients. | Evangelos Koustas Panagiotis Sarantis Athanassios G Papavassiliou Michalis V Karamouzis | 2018 | World Journal of Gastrointestinal Oncology2018，10，11： | 3 |
| 6 | Ability of bone graft substitutes to support the osteoprogenitor cells: An in-vitro study显示文摘AIM: To compare seven commercially available bone graft substitutes(BGS) in terms of these properties and without using any additional biological growth factors.METHODS: Porcine osteoprogenitor cells were loaded on seven commercially available BGS and allowed to proliferate for one week followed by osteogenic induction. Staining for live/dead cells as well as scanning electron microscopy(SEM) was carried out to determine viability and cellular binding. Further outcome measures included alkaline phosphatase(ALP) assays with normalisation for DNA content to quantify osteogenic potential. Negative and positive control experiments were carried out in parallel to validate the results.RESULTS: Live/dead and SEM imaging showed higher viability and attachment with β-tricalcium phosphate(β-TCP) than with other BGS(P < 0.05). The average ALP activity in nmol/mL(normalised value for DNA content in nmol/μg DNA) per sample was 657.58(132.03) for β-TCP, 36.22(unable to normalise) for calcium sulphate, 19.93(11.39) for the Hydroxyapatite/Tricalcium Phosphate composite, 14.79(18.53) for polygraft, 13.98(8.15) for the highly porous β-Tricalcium Phosphate, 5.56(10.0) for polymers, and 3.82(3.8) for Hydroxyapatite.CONCLUSION: Under the above experimental conditions, β-TCP was able to maintain better the viability of osteoprogenitor cells and allow proliferation and differentiation(P < 0.05). | Ziad Dahabreh Michalis Panteli Ippokratis Pountos Mark Howard Peter Campbell Peter V Giannoudis | 2014 | World Journal of Stem Cells2014，6，4： | 3 |
| 7 | Incorporated evaporative condenser 显示文摘 | Michalis G V Andronikos E F Georgios T K | 2007 | Applied Thermal Eng2007，27，56： | 1 |
| 8 | The power and promise of rewiring the mitogenactivated protein kinase network in prostate cancer therapeutics显示文摘 | ATHANASIOS G MICHALIS V | 2007 | Mol Cancer Ther2007，6，： | 1 |
| 9 | On clustering validation techniques 显示文摘 | Maria H Yannis B Michalis V | 2001 | Journal of Intelligent Information Systems2001，17，2： | 1 |
| 10 | Is amiodarone a safe antiarrhythmic to use in supraventricular tachyarrhythmias after lung cancer surgery? 显示文摘 | NIKOLAOS B MICHALIS V | 2004 | BMC Surgery2004，4，6： | 1 |
| 11 | Incorporated evaporative condenser显示文摘 | Michalis G V Andronikos E F Georgios T K | 2007 | Applied Thermal Eng2007，27，56： | 1 |
| 12 | Functional interplay between the dna-damage-response kinase atm and arf tumour suppressor protein in human cancer 显示文摘 | GEORGIA V MICHALIS L KONSTANTINOS V | 2013 | nature cell biology2013，15，8： | 1 |
| 13 | A Novel Adaptive Protocol for Light Weight Effi-cient Multicasting in Ad Hoc Networks 显示文摘 | Lap Kong Law Srikanth V Krishnamurthy Michalis Fa-loutsos | 2007 | ComputerNetworks : International Journal of Computer and Tele-communications Networking2007，51，3： | 1 |
| 14 | Cost analysis and outcomes of simple elbow dislocations显示文摘AIM: To evaluate the management, clinical outcome and cost implications of three different treatment regimes for simple elbow dislocations.METHODS: Following institutional board approval, we performed a retrospective review of all consecutive patients treated for simple elbow dislocations in a Level Ⅰ trauma centre between January 2008 and December 2010. Based on the length of elbow immobilisation(LOI), patients were divided in three groups(Group I, < 2 wk; Group Ⅱ, 2-3 wk; and Group Ⅲ, > 3 wk). Outcome was considered satisfactory when a patient could achieve a pain-free range of motion ≥ 100°(from 30° to 130°). The associated direct medical costs for the treatment of each patient were then calculated and analysed.RESULTS: We identified 80 patients who met the inclusion criteria. Due to loss to follow up, 13 patients were excluded from further analysis, leaving 67 patients for the final analysis. The mean LOI was 14 d(median 15 d; range 3-43 d) with a mean duration of hospital engagement of 67 d(median 57 d; range 10-351 d). Group Ⅲ(prolonged immobilisation) had a statistically significant worse outcome in comparison to Group Ⅰ?and Ⅱ(P = 0.04 and P = 0.01 respectively); however, there was no significant difference in the outcome between groups Ⅰ?and Ⅱ(P = 0.30). No statistically significantdifference in the direct medical costs between the groups was identified.CONCLUSION: The length of elbow immobilization doesn't influence the medical cost; however immobilisation longer than three weeks is associated with persistent stiffness and a less satisfactory clinical outcome. | Michalis Panteli Ippokratis Pountos Nikolaos K Kanakaris Theodoros H Tosounidis Peter V Giannoudis | 2015 | World Journal of Orthopedics2015，6，7： | 1 |
| 15 | Molecular dynamics simulations of the diffusion coefficients of light n-alkanes in water over a wide range of temperature and pressure显示文摘 | MICHALIS V K MOULTOS O A TSIMPANOGIANNIS I N | 2016 | Fluid Phase Equilibria2016，407，： | 1 |
| 16 | On Clustering Validation Techniques显示文摘 | Maria H Yannis B Michalis V | 2001 | Journal of Intelligent Information Systems2001，17，23： | 1 |
| 17 | Head and neck cancer显示文摘 | Athanassios Argiris Michalis V Karamouzis David Raben Robert L Ferris | 2008 | The Lancet2008，，9625： | 1 |
| 18 | Role of autophagy in cholangiocarcinoma:An autophagy-based treatment strategy显示文摘Cholangiocarcinomas(CCAs)are diverse biliary epithelial tumours involving the intrahepatic,perihilar and distal parts of the biliary tree.The three entirely variable entities have distinct epidemiology,molecular characteristics,prognosis and strategy for clinical management.However,many cholangiocarcinoma tu-mor-cells appear to be resistant to current chemotherapeutic agents.The role of autophagy and the therapeutic value of autophagy-based therapy are largely unknown in CCA.The multistep nature of autophagy offers a plethora of re-gulation points,which are prone to be deregulated and cause different human diseases,including cancer.However,it offers multiple targetable points for designing novel therapeutic strategies.Tumor cells have evolved to use auto-phagy as an adaptive mechanism for survival under stressful conditions such as energy imbalance and hypoxic region of tumors within the tumor microenvir-onment,but also to increase invasiveness and resistance to chemotherapy.The purpose of this review is to summarize the current knowledge regarding the interplay between autophagy and cholangiocarcinogenesis,together with some preclinical studies with agents that modulate autophagy in order to induce tumor cell death.Altogether,a combinatorial strategy,which comprises the current anti-cancer agents and autophagy modulators,would represent a positive CCA patient approach. | Evangelos Koustas Eleni-Myrto Trifylli Panagiotis Sarantis Athanasios G Papavassiliou Michalis V Karamouzis | 2021 | World Journal of Gastrointestinal Oncology2021，13，10： | 1 |
| 19 | 头颈癌显示文摘头颈部癌症多为鳞状细胞癌,常为暴露于烟草、酒精等致癌物后发生于上呼吸道或上消化道上皮。人乳头瘤病毒更是其某些亚型的致病因素。头颈癌累及的部位解剖结构复杂、生理功能极其重要,因此其治疗目标不仅是要提高患者的存活率,而且要保全相应器官的功能。目前,头颈癌治疗的主要进展体现在外科手术与放疗分割模式方面。此外,包括化疗与分子靶向药物(即表皮生长因子受体抑制剂)治疗在内的系统治疗,已经成功整合入局部晚期头颈鳞状细胞癌的治疗方案中。在选择个体化的治疗策略时,需重点考虑的因素包括:器官功能的预期结果、治疗耐受性以及伴发疾病等。优化评估与治疗决策的关键是开展更多的专业合作。本文对头颈部鳞状细胞癌的流行病学、分子发病机制、诊断与分期,以及最新的多模式治疗等进行回顾。 | Athanassios Argiris Michalis V Karamouzis David Raben Robert L Ferris 王顺涛(译) | 2009 | 世界临床医学2009，3，3： | 0 |
| 20 | Implication of gut microbiome in immunotherapy for colorectal cancer显示文摘Colorectal cancer(CRC) constitutes the third most frequently reported malignancy in the male population and the second most common in women in the last two decades. Colon carcinogenesis is a complex, multifactorial event, resulting from genetic and epigenetic aberrations, the impact of environmental factors, as well as the disturbance of the gut microbial ecosystem. The relationship between the intestinal microbiome and carcinogenesis was relatively undervalued in the last decade. However, its remarkable effect on metabolic and immune functions on the host has been in the spotlight as of recent years. There is a strong relationship between gut microbiome dysbiosis, bowel pathogenicity and responsiveness to anti-cancer treatment;including immunotherapy. Modifications of bacteriome consistency are closely associated with the immunologic response to immunotherapeutic agents. This condition that implies the necessity of gut microbiome manipulation. Thus, creatingan optimal response for CRC patients to immunotherapeutic agents. In this paper, we will review the current literature observing how gut microbiota influence the response of immunotherapy on CRC patients. | Evangelos Koustas Eleni-Myrto Trifylli Panagiotis Sarantis Nikolaos Papadopoulos Georgios Aloizos Ariadne Tsagarakis Christos Damaskos Nikolaos Garmpis Anna Garmpi Athanasios G Papavassiliou Michalis V Karamouzis | 2022 | World Journal of Gastrointestinal Oncology2022，14，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员